Areas of Expertise include: Business Planning Financing Strategies Operations Strategy Turnaround Management
Jim Neal has more than thirty years of experience in the biotechnology industry encompassing roles in R&D, business development, financing and general management. Most recently Jim was the Chief Executive Officer and member of the board of XOMA (NASDAQ: XOMA)and led the company through a dramatic strategic pivot taking the company from a traditional R&D heavy biotech company, transforming it to a successful royalty monetization and aggregation company. In the years prior to becoming CEO of XOMA, he was instrumental in leading the company’s licensing and business development activities focused on maximizing the value of XOMA’s foundational antibody IP and know-how. Prior to joining XOMA, Jim was Acting Chief Executive Officer of Entelos, a leading bio-simulation company that acquired Iconix Biosciences, a privately held company where Jim was Chief Executive Officer. At Iconix, he established multi-year collaborations with Bristol-Myers Squibb, Abbott Labs (now AbbVie), Eli Lilly and the U.S. Food and Drug Administration. From 1999-2002, he was Executive Vice President of Incyte Genomics, leading global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis, GSK and others. Earlier in his career, he was an executive with Monsanto Company in positions of increasing responsibility.
Currently Jim serves on the boards of several public and private biotech companies that are developing pre-commercial therapeutic candidates across an array of therapeutic areas, with a focus on oncology and immunology.
Jim earned his BS in biology and his MS in genetics and plant breeding from the University of Manitoba, Canada, and holds an MBA degree from Washington University in St. Louis, Missouri.